Kronos’ Bischofberger Turns To Gilead SYK Inhibitors To Jump Start R&D

Two years after Bischofberger left Gilead for Kronos, he called upon former colleagues to acquire a SYK inhibitor program for a genetically defined subset of acute myelogenous leukemia.

SC2007_Moving_1094693954_1200.jpg
Bischofberger is jumpstarting R&D by bringing in compounds from his prior company

While Kronos Bio, Inc. is discovering and developing transcription factor-targeting cancer therapies in house, CEO Norbert Bischofberger has turned to his former home to accelerate Kronos’ business strategy by acquiring a pair of abandoned Phase II SYK inhibitors.

Privately held Kronos revealed on 16 July that it is acquiring the mid-stage compounds entospletinib and lanraplenib, which were halted...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.